PT - JOURNAL ARTICLE AU - Vlasschaert, Caitlyn AU - McNaughton, Amy J. M. AU - Hopman, Wilma AU - Kestenbaum, Bryan AU - Robinson-Cohen, Cassianne AU - Garland, Jocelyn AU - Moran, Sarah M. AU - Holden, Rachel AU - Lanktree, Matthew B. AU - Rauh, Michael J. TI - Clonal hematopoiesis of indeterminate potential is associated with worse kidney function and anemia in a cohort of patients with advanced chronic kidney disease AID - 10.1101/2021.06.30.21259343 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.30.21259343 4099 - http://medrxiv.org/content/early/2021/07/02/2021.06.30.21259343.short 4100 - http://medrxiv.org/content/early/2021/07/02/2021.06.30.21259343.full AB - Background Clonal hematopoiesis of indeterminate potential (CHIP) is an inflammatory premalignant disorder resulting from acquired genetic mutations in hematopoietic stem cells. CHIP is common in aging populations and associated with cardiovascular morbidity and overall mortality, but its role in chronic kidney disease (CKD) has not been investigated.Methods We performed targeted sequencing to detect CHIP mutations in a cohort of 87 adults with eGFR < 60 ml/min/1.73m2. Kidney function, hematologic, and mineral bone disease parameters were assessed cross-sectionally at baseline, and a total of 2,091 creatinine measurements and 3,382 hemoglobin measurements were retrospectively collected over the following 12-year period.Results At baseline, 20 of 87 (23%) cohort participants had CHIP detected. Those with CHIP had lower baseline eGFR (22.3 ± 11.2 vs. 28.2 ± 11.5 ml/min/1.73 m2, P = 0.04) in age- and sex-adjusted regression models. Individuals with CHIP had a 2.5–fold increased risk of incident 50% decline in eGFR or ESKD in a Cox proportional hazard model adjusted for age and sex (95% confidence interval, 1.3–4.7). The annualized rate of eGFR decline adjusted for age and sex was -2.3 ±1.1 ml/min/1.73m2 per year in those with CHIP versus -1.6 ±0.5 ml/min/1.73m2 per year in those without CHIP. Further, those with CHIP had lower hemoglobin at baseline (11.6 ± 0.3 vs. 12.8 ± 0.2 g/dL, P = 0.0003) and throughout the follow-up period despite a greater use of erythropoiesis-stimulating agents.Conclusion In those with pre-existing CKD, CHIP was associated with lower eGFR at baseline, faster progression of CKD, and anemia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by a PSI Foundation Grant awarded to CV and MJR. MBL is supported by a Kidney Research Scientist Core Education and National Training (KRESCENT) Program New Investigator Award (cosponsored by the Kidney Foundation of Canada, the Canadian Society of Nephrology, and Canadian Institutes of Health Research).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Queens University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board (file 6023740).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A